The clinical effectiveness agency for England and Wales says that it will not recommend two cancer drugs, one to treat a bone cancer primarily affecting young people and another to treat metastatic breast cancer, citing limited data and high costs. The National Institute for Health and Clinical Excellence, in draft guidance issued July 9, said that mifamurtide, an immune macrophage stimulant is not recommended to treat high-grade non-metastatic osteosarcoma in people younger than 30 because of inadequate...